[
  {
    "ts": null,
    "headline": "Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025",
    "summary": "Baron Capitalâs Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and what investors should watch next.",
    "url": "https://finnhub.io/api/news?id=0a3f18f4fd087a83164502be0872194a010302517a4e2dbfb87d9f212ec6b9f0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754603100,
      "headline": "Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025",
      "id": 136263799,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359152753/image_1359152753.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "Baron Capitalâs Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and what investors should watch next.",
      "url": "https://finnhub.io/api/news?id=0a3f18f4fd087a83164502be0872194a010302517a4e2dbfb87d9f212ec6b9f0"
    }
  },
  {
    "ts": null,
    "headline": "Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts",
    "summary": "Baron Capital highlights biotech and robotic surgery as key growth drivers in Q2. See which stocks surged, which stumbled, and what it means for investors.",
    "url": "https://finnhub.io/api/news?id=7d86a5f952b8aef60d83bf8e084ec8106b6fbbc61886a38aee4bbe584e1b4aa3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754602500,
      "headline": "Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts",
      "id": 136263737,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2170605183/image_2170605183.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "Baron Capital highlights biotech and robotic surgery as key growth drivers in Q2. See which stocks surged, which stumbled, and what it means for investors.",
      "url": "https://finnhub.io/api/news?id=7d86a5f952b8aef60d83bf8e084ec8106b6fbbc61886a38aee4bbe584e1b4aa3"
    }
  },
  {
    "ts": null,
    "headline": "Precipio: Cash Flow Positivity May Remove Going Concern Language",
    "summary": "Deep Sail Capital highlights Precipioâs path to cash flow positivity and niche growth in cancer diagnostics. See why its turnaround story deserves a closer look.",
    "url": "https://finnhub.io/api/news?id=c384ce4b6028ab55765fe4386e474bfc60535242c93ca10f772e172fe22d64de",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754595900,
      "headline": "Precipio: Cash Flow Positivity May Remove Going Concern Language",
      "id": 136263091,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295493003/image_1295493003.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "Deep Sail Capital highlights Precipioâs path to cash flow positivity and niche growth in cancer diagnostics. See why its turnaround story deserves a closer look.",
      "url": "https://finnhub.io/api/news?id=c384ce4b6028ab55765fe4386e474bfc60535242c93ca10f772e172fe22d64de"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market",
    "summary": "Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market",
    "url": "https://finnhub.io/api/news?id=d45864633bccb418040697288f255b3c544a3b9587c99869ff29de9818162ee0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754584500,
      "headline": "Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market",
      "id": 136297659,
      "image": "",
      "related": "TMO",
      "source": "MarketWatch",
      "summary": "Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market",
      "url": "https://finnhub.io/api/news?id=d45864633bccb418040697288f255b3c544a3b9587c99869ff29de9818162ee0"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Active Pharmaceutical Ingredients CDMO Market Report 2025-2030 | Competitive Analysis of Thermo Fisher Scientific, Novo Group, Cambrex, Piramal, Corden, Siegfried, Seqens, SK, Noramco, BSP",
    "summary": "The U.S. Active Pharmaceutical Ingredients CDMO market, valued at USD 25.28 billion in 2024, is projected to grow at a 5.1% CAGR, reaching USD 33.86 billion by 2030. Growth factors include rising demand for innovative drug development, advancements in manufacturing automation, and a focus on biologics and personalized medicine. U.S. Active Pharmaceutical Ingredients CDMO Market U.S. Active Pharmaceutical Ingredients CDMO Market Dublin, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The \"U.S. Active Pharmaceu",
    "url": "https://finnhub.io/api/news?id=d17c679262a36110e96cd5ece845435ba4b057011742479e5006e90281a78475",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754571720,
      "headline": "U.S. Active Pharmaceutical Ingredients CDMO Market Report 2025-2030 | Competitive Analysis of Thermo Fisher Scientific, Novo Group, Cambrex, Piramal, Corden, Siegfried, Seqens, SK, Noramco, BSP",
      "id": 136246310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The U.S. Active Pharmaceutical Ingredients CDMO market, valued at USD 25.28 billion in 2024, is projected to grow at a 5.1% CAGR, reaching USD 33.86 billion by 2030. Growth factors include rising demand for innovative drug development, advancements in manufacturing automation, and a focus on biologics and personalized medicine. U.S. Active Pharmaceutical Ingredients CDMO Market U.S. Active Pharmaceutical Ingredients CDMO Market Dublin, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The \"U.S. Active Pharmaceu",
      "url": "https://finnhub.io/api/news?id=d17c679262a36110e96cd5ece845435ba4b057011742479e5006e90281a78475"
    }
  },
  {
    "ts": null,
    "headline": "Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service",
    "summary": "FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient outcomes DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of a new testing service for preeclampsia, a sign",
    "url": "https://finnhub.io/api/news?id=10fefe7e0bd76184a8cdf11ff7d318ea6c9a16164dc04c85052a4de6875ac96e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754568000,
      "headline": "Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service",
      "id": 136246311,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient outcomes DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of a new testing service for preeclampsia, a sign",
      "url": "https://finnhub.io/api/news?id=10fefe7e0bd76184a8cdf11ff7d318ea6c9a16164dc04c85052a4de6875ac96e"
    }
  }
]